Lexeo Therapeutics’ (LXEO) Buy Rating Reiterated at HC Wainwright

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $23.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. Royal Bank of Canada dropped their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. Finally, Leerink Partners lowered their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday, March 24th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Buy” and a consensus target price of $22.20.

Lexeo Therapeutics Trading Up 29.7 %

LXEO opened at $2.36 on Tuesday. The stock has a market capitalization of $78.34 million, a PE ratio of -0.75 and a beta of 1.52. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $19.50. The firm’s fifty day moving average price is $3.47 and its 200 day moving average price is $6.06. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09. As a group, research analysts expect that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allostery Investments LP bought a new stake in Lexeo Therapeutics in the 4th quarter valued at approximately $33,000. BNP Paribas Financial Markets raised its position in Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $46,000. JPMorgan Chase & Co. grew its stake in Lexeo Therapeutics by 135.6% during the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after purchasing an additional 5,915 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $69,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.